Torchelsen, Fernanda Karoline Vieira da SilvaSilva, Thaila MartinsMilagre, Matheus MarquesSilva, Rafael RodriguesReis, Levi Eduardo SoaresBranquinho, Renata TupinambáSilva, Glenda Nicioli daLana, Marta de2021-09-132021-09-132020TORCHELSEN, F. K. V. da S. et al. Evaluation of the anti-Trypanosoma cruzi activity in vitro and in vivo of silibinin and silibinin in association to benznidazole. Parasitology Research, v. 120, p. 1511-1517, nov. 2020. Disponível em: <https://link.springer.com/article/10.1007/s00436-020-06944-5>. Acesso em: 10 jun. 2021.1432-1955http://www.repositorio.ufop.br/jspui/handle/123456789/13697Chagas disease (CD) is endemic in Latin America. Drugs available for its treatment are benznidazole (BZ)/nifurtimox (NF), both with low efficacy in the late infection and responsible for several side effects. Studies of new drugs for CD among natural products, and using drug combinations with BZ/NF are recommended. Silibinin (SLB) is a natural compound that inhibits the efflux pump (Pgp) of drugs in host cell membranes, causes death of trypanosomatids, has anti-inflammatory activity, and was never assayed against T. cruzi. Here, in vitro and in vivo activities of SLB, SLB+BZ, and BZ against T. cruzi Y strain were evaluated. Cytotoxicity of SLB in VERO cells by the MTT method revealed IC50 of 250.22 μM. The trypanocidal activity evaluated by resazurin method in epimastigotes showed that SLB 25 μM inhibited parasite growth. SLB IC50 and selectivity index (SI) for amastigote were 79.81 μM and 3.13, respectively. SLB100+BZ10 showed higher parasite inhibition (91.44%) than SLB or BZ. Swiss mice infected with Y strain were treated with SLB, SLB+BZ, and BZ. Parasitemia was evaluated daily and 90, 180, and 240 days after treatment in surviving animals by hemoculture, blood qPCR, and after euthanasia, by qPCR in heart tissue. SLB monotherapy was not able to control the parasitemia/mortality of the animals. Parasitological negativation of 85.7– 100% was observed in the experimental groups treated with SLB+BZ. Although SLB had shown activity against T. cruzi in vitro, it was not active in mice. Thus, the results of the therapeutic effect observed with SLB+BZ may be interpreted as a result from BZ action.en-USrestritoDrug associationArtigo publicado em periodicohttps://link.springer.com/article/10.1007/s00436-020-06944-5https://doi.org/10.1007/s00436-020-06944-5